Overview

Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy

Status:
Completed
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
We aimed to assess changes in pancreatic fat content in people with diabetes on dapagliflozin (SGLT2 inhibitor) and beta cell function.
Phase:
Phase 4
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research
Treatments:
Dapagliflozin